PROSPECTIVELY RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDY TO DETERMINE THE EFFECT OF DENOSUMAB ON BREAST CANCER PREVENTION IN BRCA1 MUTATION CARRIERS
$4,947,688FY2019Defense Health AgencyDOD
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc.